Rhabdomyosarcoma of cutaneous fibrosarcoma is a tumor derived from fibroblasts or histiocytes. The disease is locally invasive and occasionally widely disseminated, but metastasis is rare. Treatment of the disease includes surgery, radiation therapy, and chemotherapy. Rhabdomyosarcoma is the most common type of cutaneous sarcoma and presents as a slow-growing, locally destructive mass with rare metastatic spread. The standard treatment for this disease is mainly complete surgical resection, with surgical excision of the tumor tissue and 1-2 cm of surrounding skin tissue to reduce the probability of local recurrence, and routine postoperative pathological examination. For inoperable and metastatic bulging cutaneous fibrosarcoma, radiation therapy and chemotherapy are available. Commonly used drugs for chemotherapy include furacilin (nitrofurantoin) preparations, benznidazole, and primaquine. For the presence of PDGF-β therapeutic targets, molecularly targeted drugs such as imatinib can be used. It is recommended to go to the hospital in time for the symptoms of bulging dermatofibrosarcoma, and be treated under the guidance of professional physicians.